Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease

Archives of Internal Medicine

Volumn 169, Issue 15, 2009, Pages 1403-1410

  Lee, Todd A ^a,b   Wilke, Caitlyn ^b   Joo, Min ^a,c   Stroupe, Kevin T ^a,d   Krishnan, Jerry A ^e   Schumock, Glen T ^b   Pickard, A Simon ^a,b  

^a HINES VA HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG USE; FEMALE; HAZARD RATIO; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CAUSE OF DEATH; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SURVIVAL ANALYSIS; VETERANS;

EID: 68849127359     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.233     Document Type: Article

References (33)

1. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. Arch Intern Med. 2008;168(2):136-140.
2. Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med. 2007;101(6):1313-1320.
3. Strom BL. Methodologic challenges to studying patient safety and comparative effectiveness. Med Care. 2007;45(10)(suppl 2):S13-S15.
4. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
5. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-1276.
6. Calverley PM, Anderson JA, Celli B, et al; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
7. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359 (15):1543-1554.
8. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr; US Tiotropium Study Group. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest. 2000;118(5):1294-1302.
9. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122(1):47-55.
10. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with oncedaily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(4, pt 1):1136-1142.
11. Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006; 73(4):420-427.
12. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther. 2005;18(2):75-81.
13. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest. 2003; 123(5):1441-1449.
14. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143(5):317-326.
15. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-1450.
16. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006;61(10):854-862.
17. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130(6):1695-1703.
18. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49-53.
19. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241-249.
20. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008; 167(4):492-499.
21. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.
22. Joo MJ, Lee TA, Weiss KB. Geographic variation in chronic obstructive pulmonary disease exacerbation rates. J Gen Intern Med. 2007;22(11):1560-1565.
23. Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest. 2006;129(6):1509-1515.
24. Stroupe KT, Smith BM, Lee TA, et al. Effect of increased copayments on pharmacy use in the Department of Veterans Affairs. Med Care. 2007;45(11):1090-1097.
25. Austin PC, Mamdani MM. A comparison of propensity score methods: a casestudy estimating the effectiveness of post-AMI statin use. Stat Med. 2006; 25(12):2084-2106 16220490.
26. Austin PC, Mamdani MM, Stukel TA, Anderson GM, Tu JV. The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med. 2005;24(10):1563-1578.
27. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19): 2265-2281.
28. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004; 23(19):2937-2960.
29. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757-763.
30. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14(7):465-476.
31. Wang J, Donnan PT, Steinke D, MacDonald TM. The multiple propensity score for analysis of dose-response relationships in drug safety studies. Pharmacoepidemiol Drug Saf. 2001;10(2):105-111.
32. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
33. Strom BL. Methodologic challenges to studying patient safety and comparative effectiveness. Med Care. 2007;45(10)(suppl 2):S13-S15.